483 related articles for article (PubMed ID: 28753789)
21. ABCC2 expression in papillary renal cell carcinoma provides better prognostic stratification than WHO/ISUP nucleolar grade.
Saleeb RM; Brimo F; Gao Y; Boulos C; Kim SS; Al Bashir S; Husain A; Rotondo F; Beharry V; Bjarnason GA; Krizova A; Trpkov K; Yousef GM
Hum Pathol; 2022 Feb; 120():57-70. PubMed ID: 34958810
[TBL] [Abstract][Full Text] [Related]
22. Recurrent KRAS mutations identified in papillary renal neoplasm with reverse polarity-a comparative study with papillary renal cell carcinoma.
Kim SS; Cho YM; Kim GH; Kee KH; Kim HS; Kim KM; Kim JH; Choi C
Mod Pathol; 2020 Apr; 33(4):690-699. PubMed ID: 31953522
[TBL] [Abstract][Full Text] [Related]
23. An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.
Wala SJ; Karamchandani JR; Saleeb R; Evans A; Ding Q; Ibrahim R; Jewett M; Pasic M; Finelli A; Pace K; Lianidou E; Yousef GM
Mol Oncol; 2015 Oct; 9(8):1667-77. PubMed ID: 26051997
[TBL] [Abstract][Full Text] [Related]
24. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma.
Klatte T; Pantuck AJ; Said JW; Seligson DB; Rao NP; LaRochelle JC; Shuch B; Zisman A; Kabbinavar FF; Belldegrun AS
Clin Cancer Res; 2009 Feb; 15(4):1162-9. PubMed ID: 19228721
[TBL] [Abstract][Full Text] [Related]
25. Correlating Transcriptional Networks to Papillary Renal Cell Carcinoma Survival: A Large-Scale Coexpression Analysis and Clinical Validation.
Feng X; Zhang M; Meng J; Wang Y; Liu Y; Liang C; Fan S
Oncol Res; 2020 May; 28(3):285-297. PubMed ID: 31948514
[TBL] [Abstract][Full Text] [Related]
26. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
Liu T; Zhang M; Sun D
Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
[TBL] [Abstract][Full Text] [Related]
27. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
[TBL] [Abstract][Full Text] [Related]
28. Identification of 4-genes model in papillary renal cell tumor microenvironment based on comprehensive analysis.
Luo L; Zhou H; Su H
BMC Cancer; 2021 May; 21(1):553. PubMed ID: 33993869
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of vascular endothelial growth factor (VEGF), VEGF receptor 2, platelet-derived growth factor-β (PDGF-β), and PDGF-β receptor expression in papillary renal cell carcinoma.
Kim M; Sohn M; Shim M; Choi SK; Park M; Kim E; Go H; Park Y; Cho YM; Ro JY; Jeong IG; Song C; Hong JH; Kim CS; Ahn H
Hum Pathol; 2017 Mar; 61():78-89. PubMed ID: 27989785
[TBL] [Abstract][Full Text] [Related]
30. MicroRNAs as prognostic molecular signatures in renal cell carcinoma: a systematic review and meta-analysis.
Gu L; Li H; Chen L; Ma X; Gao Y; Li X; Zhang Y; Fan Y; Zhang X
Oncotarget; 2015 Oct; 6(32):32545-60. PubMed ID: 26416448
[TBL] [Abstract][Full Text] [Related]
31. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
32. A molecular classification of papillary renal cell carcinoma.
Yang XJ; Tan MH; Kim HL; Ditlev JA; Betten MW; Png CE; Kort EJ; Futami K; Furge KA; Takahashi M; Kanayama HO; Tan PH; Teh BS; Luan C; Wang K; Pins M; Tretiakova M; Anema J; Kahnoski R; Nicol T; Stadler W; Vogelzang NG; Amato R; Seligson D; Figlin R; Belldegrun A; Rogers CG; Teh BT
Cancer Res; 2005 Jul; 65(13):5628-37. PubMed ID: 15994935
[TBL] [Abstract][Full Text] [Related]
33. The underlying molecular mechanism and potential drugs for treatment in papillary renal cell carcinoma: A study based on TCGA and Cmap datasets.
Pang JS; Li ZK; Lin P; Wang XD; Chen G; Yan HB; Li SH
Oncol Rep; 2019 Apr; 41(4):2089-2102. PubMed ID: 30816528
[TBL] [Abstract][Full Text] [Related]
34. Papillary Renal Cell Carcinoma With Microcystic Architecture Is Strongly Associated With Extrarenal Invasion and Metastatic Disease.
Chan E; Stohr BA; Butler RS; Cox RM; Myles JL; Nguyen JK; Przybycin CG; Reynolds JP; Williamson SR; McKenney JK
Am J Surg Pathol; 2022 Mar; 46(3):392-403. PubMed ID: 34881751
[TBL] [Abstract][Full Text] [Related]
35. Pathology, therapy and prognosis of papillary renal carcinoma.
Fernandes DS; Lopes JM
Future Oncol; 2015; 11(1):121-32. PubMed ID: 25572787
[TBL] [Abstract][Full Text] [Related]
36. Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma.
Wang Y; Tian X; Zhu SX; Xu WH; Anwaier A; Su JQ; Gan HL; Qu YY; Zhao JY; Zhang HL; Ye DW
World J Surg Oncol; 2023 Mar; 21(1):98. PubMed ID: 36927438
[TBL] [Abstract][Full Text] [Related]
37. In silico DNA methylation analysis identifies potential prognostic biomarkers in type 2 papillary renal cell carcinoma.
Yang M; Hlady RA; Zhou D; Ho TH; Robertson KD
Cancer Med; 2019 Sep; 8(12):5760-5768. PubMed ID: 31361072
[TBL] [Abstract][Full Text] [Related]
38. Molecular Subtypes of Clear-cell Renal Cell Carcinoma are Prognostic for Outcome After Complete Metastasectomy.
Verbiest A; Couchy G; Job S; Caruana L; Lerut E; Oyen R; de Reyniès A; Tosco L; Joniau S; Van Poppel H; Van Raemdonck D; Van Den Eynde K; Wozniak A; Zucman-Rossi J; Beuselinck B
Eur Urol; 2018 Oct; 74(4):474-480. PubMed ID: 29463434
[TBL] [Abstract][Full Text] [Related]
39. Bioinformatics profiling integrating a four immune-related long non-coding RNAs signature as a prognostic model for papillary renal cell carcinoma.
Liu Y; Gou X; Wei Z; Yu H; Zhou X; Li X
Aging (Albany NY); 2020 Jul; 12(15):15359-15373. PubMed ID: 32716909
[TBL] [Abstract][Full Text] [Related]
40. Comparison of clinicopathologic parameters and oncologic outcomes between type 1 and type 2 papillary renal cell carcinoma.
Le X; Wang XB; Zhao H; Chen RF; Ge P
BMC Urol; 2020 Sep; 20(1):148. PubMed ID: 32933514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
